Skip to content

Agios (NASDAQ: AGIO), founded in 2007, is a publicly-traded biopharmaceutical company discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active R&D pipeline, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.

Latest Press from Agios Pharmaceuticals

Next